UBT251
Sources
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07648225
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 600. Conditions Obesity & Overweight. This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
ClinicalTrials.gov NCT07648225 protocol and results modules
registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07767942
UBT251 Injection Phase Ⅲ Study (OSA-NPAP). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 150. Conditions Obstructive Sleep Apnea, Obesity. The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety. The key research question is: Does UBT251 reduce the Apnea-Hypopnea
ClinicalTrials.gov NCT07767942 protocol and results modules
registry, as of 2026-09-08Stale
https://clinicaltrials.gov/study/NCT07806851
UBT251 Injection Phase Ⅲ Study (OSA-PAP). Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 150. Conditions Obstructive Sleep Apnea; Obesity. UBT251 will be compared with placebo (an inactive substance identical in appearance) to evaluate its therapeutic effect in participants with moderate-to-severe obstructive sleep apnea maintained on positive airway pressure therapy.Participants will complete the following study pr
ClinicalTrials.gov NCT07806851 protocol and results modules
registry, as of 2026-04-21Stale
https://clinicaltrials.gov/study/NCT07395687
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 333. Conditions Overweight; Obesity. The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which trea
ClinicalTrials.gov NCT07395687 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07177469
UBT251 Injection Phase II Study (Overweight or Obesity). Overall status COMPLETED. Phases PHASE2. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 205. Conditions Obesity &Amp; Overweight. This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
ClinicalTrials.gov NCT07177469 protocol and results modules
registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07134335
UBT251 Injection Phase II Clinical Study (CKD). Overall status RECRUITING. Phases PHASE2. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 180. Conditions Obesity &Amp; Overweight; Chronic Kidney Disease. This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
ClinicalTrials.gov NCT07134335 protocol and results modules
registry, as of 2026-08-25Stale
https://clinicaltrials.gov/study/NCT07785934
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor The United Bio-Technology (Hengqin) Co., Ltd.. Enrollment 48. Conditions Drug Drug Interaction (DDI); Pharmacokinetics and Pharmacodynamics. This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity. The primary objective of Cohort 1 is to evaluate the effect of UBT251 Injection on the pha
ClinicalTrials.gov NCT07785934 protocol and results modules
registry, as of 2026-08-18Stale
https://clinicaltrials.gov/study/NCT07710768
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 44. Conditions Obesity; Overweight. The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.
ClinicalTrials.gov NCT07710768 protocol and results modules
publication, as of 2026-10-23Stale
https://pubmed.ncbi.nlm.nih.gov/42843337/
agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial. UBT251 is a novel triple agonist targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. In this multicenter, randomized, double-blind, placebo-controlled phase 2
PMID 42843337